The short version of HGF mimetic fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-12-31 and is reviewed periodically as new material appears.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical lyophilized research form. |
| Solubility | Soluble in DMSO; limited in water | Depends on purity and salt form. |
| Storage temperature | -20 °C or lower | Desiccated and protected from light. |
| Analytical method | RP-HPLC and LC-MS | Common for purity and identity. |
| Regulatory status | Research chemical in many countries | Not widely approved as a medicine. |
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
== Pharmacology == The basic pharmacophore, or active structure, of the fluoroquinolone class is based upon the quinoline ring system. Various substitutions made to the quinoline ring resulted in the development of numerous fluoroquinolone drugs. The addition of the fluorine atom at C-6 distinguishes the successive-generation fluoroquinolones from the first-generation quinolones, although examples are known that omit the atom while retaining antibacterial activity.
==== Blockage of the ejaculatory duct ==== This is a condition that is caused by obstruction of either one or both ejaculatory ducts leading to hypospermia. The etiology of ejaculatory duct obstruction can be congenital or acquired. The presence of a prostatic cysts, ejaculatory duct stones, or post surgical inflammation of the duct can block the normal flow of semen through the reproductive tract.
=== Lung toxicity === Some studies suggest that perchlorate has toxic effects against lungs (pulmonary toxicity) as well. Studies have been performed on rabbits where perchlorate has been injected into the trachea. The lung tissue was removed and analyzed, and it was found that perchlorate injected lung tissue showed several adverse effects when compared to the control group that had been intratracheally injected with saline. Adverse effects included inflammatory infiltrates, alveolar collapse, subpleural thickening, and lymphocyte proliferation.
Sources: en.wikipedia.org
=== With other depressant drugs === The concurrent use of opioids with other depressant drugs such as benzodiazepines or ethanol increases the rates of adverse events and overdose. Despite this, opioids and benzodiazepines are concurrently dispensed in many settings. As with an overdose of opioid alone, the combination of an opioid and another depressant may precipitate respiratory depression often leading to death. These risks are lessened with close monitoring by a physician, who may conduct ongoing screening for changes in patient behavior and treatment compliance.
where Fi is blood flow (noted Q in the Figure above), Cart incoming arterial blood concentration, Pi the tissue over blood partition coefficient and Vi the volume of compartment i. A complete set of differential equations for the 7-compartment model shown above could therefore be given by the following table:
=== India === G. N. Singh, India's top drug regulator, said in a 2014 interview: "If I have to follow U.S. standards in inspecting facilities supplying to the Indian market, […] we will have to shut almost all of those." According to Outsourcing Pharma in 2012, 75% of counterfeit drugs supplied worldwide had some origins in India, followed by 7% from Egypt and 6% from China. In 2009, the Central Drug Standards Control Organisation (CDSCO), the drug regulatory authority of India conducted a nationwide survey, and announced that of "24,000 samples [that] were collected from all over India and tested. It was found that only 11 samples or 0.046% were spurious." In 2017 a similar survey found 3.16% of the medicines sampled were substandard and 0.0245% were fake. Those more commonly prescribed are probably more often faked. In 2017, industry body ASSOCHAM wrote in the paper "Fake and Counterfeit Drugs In India –Booming Biz" that fake drugs constitute US$4.25 billion of the total US$14–17 billion of domestic drug market. Around 25% of India's drugs are fake, counterfeit or substandard. If the fake drugs market grows at the current rate of 25%, it will cross the US$10 billion mark by 2017. Trade in fake drugs is driven caused by lack of adequate regulations, shortage of drug inspectors and a lack of lab facilities to check the purity of drugs. Other key factors include storage of spurious drugs by chemists, weaknesses in drug distribution system, lack of awareness among consumers and lack of law enforcement.
== Life cycle == Blastocystis hominis has a multistage life cycle and is highly adaptable to a variety of host environments. The illness develops when the cyst form is consumed by contaminated food or water. When the cyst enters the colon, it grows into a vacuolar form, which is the key diagnostic stage usually seen in stool samples. The organism has two separate transmission patterns: external transmission and self-infection. During external transmission, thick-walled cysts discharged in feces can survive in the environment and stay infectious for long periods. These environmentally resistant cysts enhance transmission between hosts via the fecal-oral pathway. In autoinfection, thin-walled cysts form from the vacuolar form and excyst within the intestine, sustaining infection in the same host. The vacuolar shape can also transform into a multi-vacuolar. It may eventually transform into an amoeboid. The amoeboid stage, while less prevalent, is thought to play a role in pathogenicity. Binary fission is the principal mode of reproduction, occurring in both vacuolar and amoeboid forms. Under stress conditions, such as unfavorable environmental factors or host immunological responses, the organism can generate pre-cyst stages that eventually develop into mature cysts. This complicated life cycle, with its numerous physical forms, helps the organism colonize and spread to a wide range of host species.
Sources: en.wikipedia.org
== Early life and education == Robinson was born in Chicago. He received a BS in chemistry from the California Institute of Technology (Caltech) in 1963, and a PhD in biochemistry from the University of California, San Diego in 1968. His doctoral thesis was titled, Experiments on the synthesis and spectral characterization of cytochrome-related molecules.
=== General === KOR agonism seems to functionally oppose multiple effects mediated by μ-opioid receptors (MOR) and δ-opioid receptors (DOR), including analgesia, tolerance, euphoria, and memory regulation. Activation of KOR by dynorphins during stress exposure has been shown to induce dysphoria, aversion, and negative affective states in both human and non-human subject. This contrasts with activation of MOR, which is associated with mood elevation and producing hedonic effects. Consequently, the KOR system has traditionally been conceptualized as mediating anti-reward processes and negative reinforcement, representing a functional counterpart to MOR in terms of behavioral and affective outcomes. However, recent research highlights a more nuanced role for KOR signaling, implicating it in a spectrum of complex behaviors and neural processes that extend beyond a strictly dichotomous and unidimensional frameworks, including functions independent of hedonic tone within reward processing. Centrally active KOR agonists have distinct, atypical dissociative hallucinogenic effects, as exemplified by salvinorin A (the active constituent in Salvia divinorum). The experiences include: dissociation, incapacitation, psychotomimesis, profound alterations in interoception, somatic sensations, visual and auditory hallucinations, synesthesia (particularly visual-proprioceptive binding), sedation, analgesia, anti-inflammation, neuroprotection, memory impairment, anti-addiction, aversion, dysphoria, anxiogeny, both antidepressant and depressogenic effect.
N-Desethyletonitazene (NDE, Noretonitazene) is a benzimidazole derivative with potent opioid effects which has been sold as a designer drug. It is better known as an active metabolite of the related compound etonitazene, but has similar activity to the parent compound and has sometimes appeared as a drug of abuse in its own right, first being identified in New Zealand in 2024.
In November 2020, Hetero signed an agreement with the Russian Direct Investment Fund (RDIF) to manufacture more than 100 million doses of Sputnik V, the world’s first registered COVID-19 vaccine. Hetero continued its response to COVID-19 with the launch of Movfor (molnupiravir) in late 2021 and Nirmacom (a generic version of nirmatrelvir-ritonavir) in 2022. In December 2022, Nirmacom became the first generic adaptation of the COVID treatment to receive WHO prequalification, allowing Hetero to distribute it to 95 LMICs under a voluntary license administered through the Medicines Patent Pool. 2023- Present In 2023, Hetero celebrated 30 years of its journey from a small-time API producer to a global pharmaceutical manufacturing powerhouse. In 2024, Hetero entered a partnership with Gilead Sciences to expand availability of Lenacapavir, a long acting injectable HIV treatment, across 120 high-incidence countries in order to support the global HIV response. In 2025, Hetero opened a new commercial office in Warsaw, Poland, marking the company’s formal entry into the Eastern European pharmaceutical markets. In 2026, Hetero launched generic versions of semaglutide - the active ingredient in medicines for type 2 diabetes and obesity management- in emerging markets under the names Truglyx, Rolmodl, and Moto G.
Dichloroacetylene (DCA) is an organochlorine compound with the formula C2Cl2. It is a colorless, pyrophoric, explosive liquid that has a sweet and "disagreeable" odor. Dichloroacetylene is neurotoxic, hepatotoxic, nephrotoxic and possibly carcinogenic.
Sources: en.wikipedia.org
The lyophilized powder is generally stored at -20 °C or lower, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data may vary by formulation and purity.
Mass spectrometry is commonly used to confirm molecular mass, while RP-HPLC estimates purity. These methods can be combined with amino acid analysis or NMR for further structural confirmation. A certificate of analysis alone does not guarantee independent verification.
Legality depends on the country and the intended use. In many places it is not approved as a drug and may be regulated as a research chemical. Buyers should check local laws and institutional policies before obtaining it.
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.